SANUWAVE Health (SNWV) 10-Q 26 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 25, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Document Transition Report	false
Entity File Number	000-52985
Entity Registrant Name	SANUWAVE Health, Inc.
Entity Central Index Key	0001417663
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	20-1176000
Entity Address, Address Line One	3360 Martin Farm Road
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Suwanee
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30024
City Area Code	770
Local Phone Number	419-7525
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		517,195,705

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current Assets:
Cash	$ 313	$ 619
Accounts receivable, net of allowance for doubtful accounts of $0.7 and $0.5, respectively	1,730	2,415
Inventory	1,001	1,040
Prepaid expenses and other current assets	365	326
Total Current Assets	3,409	4,400
Property and Equipment, net	315	668
Right of Use Assets, net	259	344
Other Intangible Assets, net	5,665	5,841
Goodwill	7,260	7,260
Other Assets	106	106
Total Assets	17,014	18,619
Current Liabilities:
Senior secured promissory note payable, in default	11,894	11,586
Convertible promissory notes payable, in default	10,532	11,601
Convertible promissory notes, related parties, in default	1,596	1,596
Advances on future cash receipts	416	446
Accounts payable	6,696	7,644
Accrued expenses	4,916	4,394
Accrued employee compensation	3,623	4,247
Due under factoring agreement	1,231	1,737
Warrant liability	8,300	9,614
Current portion of SBA loans	226	158
Accrued interest	3,072	2,521
Accrued interest, related parties	345	289
Current portion of lease liabilities	268	268
Current portion of contract liabilities	58	48
Other	58	114
Total Current Liabilities	53,231	56,263
Non-current Liabilities
SBA loans	807	875
Lease liabilities	34	118
Contract liabilities	303	293
Deferred tax liability	28	28
Total Non-current Liabilities	1,172	1,314
Total Liabilities	54,403	57,577
Commitments and Contingencies (Footnote 11)
STOCKHOLDERS' DEFICIT
Preferred Stock, par value $0.001, 5,000,000 shares authorized; 6,175, 293, 90 and 8 shares designated Series A, Series B, Series C and Series D, respectively; no shares issued and outstanding at March 31, 2022 and December 31, 2021	0	0
Common Stock, par value $0.001, 800,000,000 shares authorized; 517,195,705 and 481,619,621 issued and outstanding at March 31, 2022 and December 31, 2021, respectively	517	482
Additional Paid-in Capital	150,533	144,582
Accumulated Deficit	(188,372)	(183,949)
Accumulated Other Comprehensive Loss	(67)	(73)
Total Stockholders' Deficit	(37,389)	(38,958)
Total Liabilities and Stockholders' Deficit	$ 17,014	$ 18,619

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current Assets:
Accounts receivable, allowance for doubtful accounts	$ 785	$ 475
STOCKHOLDERS' DEFICIT
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	800,000,000	800,000,000
Common stock, shares issued (in shares)	517,195,705	481,619,621
Common stock, shares outstanding (in shares)	517,195,705	481,619,621
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, shares authorized (in shares)	6,175	6,175
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, shares authorized (in shares)	293	293
Series C Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, shares authorized (in shares)	90	90
Series D Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, shares authorized (in shares)	8	8

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues:
Total Revenue	$ 3,195	$ 2,116
Cost of Revenues	889	1,055
Gross Margin	2,306	1,061
Operating Expenses:
General and administrative	2,141	3,129
Selling and marketing	1,715	1,780
Research and development	166	354
Gain on disposal of assets	(554)	0
Depreciation and amortization	176	192
Total Operating Expenses	3,644	5,455
Operating Loss	(1,338)	(4,394)
Other Income (Expense):
Interest expense	(3,076)	(1,122)
Interest expense, related party	(56)	(47)
Change in fair value of derivative liabilities	3,482	635
Loss on issuance of debt	(3,434)	0
Gain / (loss) on foreign currency exchange	(1)	7
Other Income (Expense), net	(3,085)	(527)
Net Loss before Income Taxes	(4,423)	(4,921)
Provision for Income Taxes	0	16
Net Loss	(4,423)	(4,937)
Other Comprehensive Loss
Foreign currency translation adjustments	0	(8)
Total Comprehensive Loss	$ (4,423)	$ (4,945)
Loss per Share:
Net loss per share - basic (in dollars per share)	$ (0.01)	$ (0.01)
Net loss per share - diluted (in dollars per share)	$ (0.01)	$ (0.01)
Weighted average shares outstanding - basic (in shares)	525,414,534	518,490,225
Weighted average shares outstanding - diluted (in shares)	525,414,534	518,490,225
Accessory and Parts Revenue [Member]
Revenues:
Total Revenue	$ 2,192	$ 1,571
Product [Member]
Revenues:
Total Revenue	645	253
Rental Income [Member]
Revenues:
Total Revenue	343	254
License Fees and Other [Member]
Revenues:
Total Revenue	$ 15	$ 38

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Beginning balance at Dec. 31, 2020	$ 0	$ 471	$ 142,563	$ (156,690)	$ (62)	$ (13,718)
Beginning balance (in shares) at Dec. 31, 2020	0	470,694,621
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cashless warrant exercise	$ 0	$ 11	(11)	0	0	0
Cashless warrant exercise (in shares)	0	10,925,000
Reclassification of warrant liability due to cashless warrant exercise	$ 0	$ 0	2,030	0	0	2,030
Reclassification of warrant liability due to cashless warrant exercise (in shares)	0	0
Net loss	$ 0	$ 0	0	(4,937)	0	(4,937)
Foreign currency translation adjustment	0	0	0	0	(8)	(8)
Ending balance at Mar. 31, 2021	$ 0	$ 482	144,582	(161,627)	(70)	(16,633)
Ending balance (in shares) at Mar. 31, 2021	0	481,619,621
Beginning balance at Dec. 31, 2021	$ 0	$ 482	144,582	(183,949)	(73)	(38,958)
Beginning balance (in shares) at Dec. 31, 2021	0	481,619,621
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cashless warrant exercise	$ 0	$ 14	2,152	0	0	2,166
Cashless warrant exercise (in shares)	0	14,000,000
Warrant exercise	$ 0	$ 1	99	0	0	100
Warrant exercise (in shares)	0	909,091
Shares issued in conjunction with Note Payable	$ 0	$ 20	3,700	0	0	3,720
Shares issued in conjunction with Note Payable (in shares)	0	20,666,993
Net loss	$ 0	$ 0	0	(4,423)	0	(4,423)
Foreign currency translation adjustment	0	0	0	0	6	6
Ending balance at Mar. 31, 2022	$ 0	$ 517	$ 150,533	$ (188,372)	$ (67)	$ (37,389)
Ending balance (in shares) at Mar. 31, 2022	0	517,195,705

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash Flows - Operating Activities:
Net loss	$ (4,423)	$ (4,937)
Adjustments to reconcile net loss to net cash used by operating activities
Amortization of intangibles	176	176
Depreciation	15	94
Bad debt expense	0	132
Income tax expense	0	16
Change in fair value of derivative liabilities	(3,482)	(635)
Loss on issuance of debt	3,434	0
Amortization of debt issuance costs and original issue discount	889	228
Accrued interest	551	(40)
Interest payable, related parties	56	47
Changes in operating assets and liabilities
Accounts receivable - trade	804	489
Inventory	39	21
Prepaid expenses	(39)	(444)
Other assets	43	(24)
Operating leases	0	(6)
Accounts payable	(930)	1,274
Accrued expenses	439	365
Accrued employee compensation	(549)	(78)
Contract liabilities	(155)	(22)
Net Cash Used by Operating Activities	(3,132)	(3,344)
Cash Flows - Investing Activities
Disposition of property and equipment	360	(101)
Net Cash Flows Provided by (Used in) Investing Activities	360	(101)
Cash Flows - Financing Activities
Proceeds from senior promissory notes	2,940	0
Proceeds from SBA loan	0	1,033
Payments for factoring	(505)	0
Proceeds from warrant exercises	100	125
Payments of principal on finance leases	(65)	(46)
Net Cash Flows Provided by Financing Activities	2,470	1,112
Effect of Exchange Rates on Cash	(4)	(8)
Net Change in Cash During Period	(306)	(2,341)
Cash at Beginning of Period	619	2,437
Cash at End of Period	313	96
Supplemental Information:
Cash paid for interest	574	934
Non-cash Investing and Financing Activities:
Reclassification of warrant liability due to cashless warrant exercise	2,167	2,030
Warrants issued in conjunction with senior secured promissory note payable	2,654	0
Common shares issued in conjunction with senior secured promissory note payable	$ 3,720	$ 0

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Nature of the Business and Basis of Presentation [Abstract]
Nature of the Business and Basis of Presentation	1. Nature of the Business and Basis of Presentation SANUWAVE Health, Inc. and Subsidiaries (“SANUWAVE” or the “Company”) is focused on the research, development, and commercialization of its patented noninvasive and biological response activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company’s lead regenerative product in the United States is the dermaPACE® device used for treating diabetic foot ulcers. Through the Company’s acquisition, on August 6, 2020, of the UltraMIST® assets from Celularity, Inc. (“Celularity”), SANUWAVE now combines two highly complementary and market-cleared energy transfer technologies and two human tissue biologic products, which creates a platform of scale with an end-to-end product offering in the advanced wound care market. Basis of Presentation – The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and disclosures required by U.S. GAAP for comprehensive financial statements. Certain accounts in the prior period condensed consolidated financial statements have been reclassified to conform to the presentation of the current period condensed consolidated financial statements. These reclassifications had no effect on the previously reported operating results. The financial information as of March 31, 2022, and for the three months ended March 31, 2022 and 2021 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three ended March 31, 2022, are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2022. The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited Consolidated Financial Statements at that date but does not include all of the information and disclosures required by U.S. GAAP for comprehensive financial statements. These financial statements should be read in conjunction with the Company’s December 31, 2021 Annual Report on Form 10-K filed with the SEC on May 13, 2022 (the “2021 Annual Report”).

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2022
Going Concern [Abstract]
Going Concern	2. Going Concern Our recurring losses from operations and dependency upon future issuances of equity or other financing to fund ongoing operations have raised substantial doubt as to our ability to continue as a going concern. We will be required to raise additional funds to finance our operations and remain a going concern; we may not be able to do so, and/or the terms of any financings may not be advantageous to us. The continuation of our business is dependent upon raising additional capital. We expect to devote substantial resources for the commercialization of the dermaPACE and will continue to research and develop the non-medical uses of the PACE technology, both of which will require additional capital resources. The operating losses and the events of default on the Company’s notes payable indicate substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the filing of this Form 10-Q. The continuation of our business is dependent upon raising additional capital to fund operations. Management’s plans are to obtain additional capital in 2022 through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the conversion of outstanding warrants, issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to our existing shareholders. In addition, there can be no assurances that our plans to obtain additional capital will be successful on the terms or timeline we expect, or at all. Although no assurances can be given, management believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for us. If these efforts are unsuccessful, we may be required to significantly curtail or discontinue operations or obtain funds through financing transactions with unfavorable terms. The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Our consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of assets and liabilities that might be necessary should we be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Significant accounting policies followed by the Company are summarized below and should be read in conjunction with those described in Note 3 to the Consolidated Financial Statements in our 2021 Annual Report. Estimates Significant estimates include the recording of allowances for doubtful accounts, the net realizable value of inventory, useful lives of long-lived assets, fair value of goodwill and other intangible assets, the determination of the valuation allowances for deferred taxes, estimated fair value of stock-based compensation, and the estimated fair value of financial instruments, including warrants and embedded conversion options.

Loss per Share

Loss per Share	3 Months Ended
	Mar. 31, 2022
Loss per Share [Abstract]
Loss per Share	4. Loss per Share The net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares outstanding for the three months ended March 31, 2022, and 2021. In accordance with ASC Topic 260-10-45-13, Earnings Per Share Accordingly, warrants issued with a $0.01 per share exercise price, are included in weighted average shares outstanding as follows (shares in s): Three Months Ended March 31, 2022 March 31, 2021 Weighted average shares outstanding Common shares 498,723 481,620 Common shares issuable assuming excercise of nominally priced warrants 26,691 36,871 Weighted average shares outstanding 525,414 518,491 Diluted net loss per share would be computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding. To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net loss per share. As a result of the net loss for the three months ended March 31, 2022 and 2021, all potentially dilutive shares were anti-dilutive and therefore excluded from the computation of diluted net loss per share. Anti-dilutive equity securities consist of the following at March 31, 2022 and 2021, respectively (in s): 2022 2021 Common stock options 31,759 31,864 Common stock purchase warrants 183,435 142,266 Convertible notes payable 94,172 60,329 309,366 234,459

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2022
Accrued Expenses [Abstract]
Accrued Expenses	5. Accrued Expenses Accrued expenses consist of the following at March and December (in s): 2022 2021 Registration penalties $ 2,083 $ 1,950 License fees 893 893 Board of director’s fees 537 507 Related party 250 - Other 1,153 1,044 $ 4,916 $ 4,394 There was no activity in the warranty reserve during the months ended March

Revenue

Revenue	3 Months Ended
	Mar. 31, 2022
Revenue [Abstract]
Revenue	6. Revenue Disaggregation of Revenue - The disaggregation of revenue is based on geographical region. All revenue is recognized at the point in time when control is transferred to our clients. The following tables present revenue from contracts with customers for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, 2022 Three Months Ended March 31, 2021 United States International Total United States International Total Accessories and parts $ 2,132 $ (4 ) $ 2,128 $ 1,435 $ 136 $ 1,571 Product 691 16 707 41 212 253 License fees and other 8 9 17 33 5 38 Topic 606 Revenue $ 2,831 $ 21 $ 2,852 $ 1,509 $ 353 $ 1,862 Rental income 343 - 343 254 - 254 Topic 842 Revenue $ 343 $ - $ 343 $ 254 $ - $ 254 Total Revenue $ 3,174 $ 21 $ 3,195 $ 1,763 $ 353 $ 2,116 Contract liabilities - March 31, 2022 December 31, 2021 Service agreements $ 361 $ 137 Deposit on future equipment purchases - 204 Total contract liabilities 361 341 Less: current portion (58 ) (48 ) Non-current contract liabilities $ 303 $ 293 During the months ended March and the Company recognized revenue related to these contract liabilities of in both and respectively, that were included in the beginning contract liability balances for each of those periods. The following table summarizes the changes in contract liabilities during the months ended March (in s): Three Months ended March 31, 2022 Three Months ended March 31, 2021 Beginning balance $ 341 $ 69 New service agreement additions 28 1 Deposit on future equipment purchases - 125 Revenue recognized (8 ) (8 ) Total contract liabilities 361 187 Less current portion (58 ) (32 ) Non-current contract liabilities $ 303 $ 155

Concentration of Credit Risk an

Concentration of Credit Risk and Limited Suppliers	3 Months Ended
	Mar. 31, 2022
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration of Credit Risk and Limited Suppliers	7. Concentration of Credit Risk and Limited Suppliers Major customers are defined as customers whose accounts receivable, or sales individually consist of more than ten percent of total trade receivables or total sales, respectively. The percentage of accounts receivable and sales from major customers of the Company for the periods indicated were as follows: March 31, 2022 December 31, 2021 Accounts Receivable: Customer A 15 % 16 % Customer B n/a 24 % March 31, 2022 March 31, Revenue: Customer A 11 % n/a The Company currently purchases most of its product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. The of purchases from major vendors of the Company that exceeded of total purchases for the months ended March and were as follows: Three Months Ended March 31, 2022 March 31, 2021 Purchases: Vendor A 19 % 55 % Vendor B n/a 13 %

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2022
Notes Payable [Abstract]
Notes Payable	8. Notes payable The following tables summarize outstanding notes payable as of March and December (dollars in s): A s of 03 / / (dollars in s) Maturity Date Interest Rate Conversion Price Principal Remaining Debt Discount Remaining Embedded Conversion Option Carrying Value Senior secured promissory note payable, in default In default 20.50 % n/a $ 18,000 (6,106 ) - $ 11,894 Convertible promissory notes payable, in default: Total convertible promisory notes payable, in default In default 15.40 % $ 0.1058 6,445 (488 ) 4,575 10,532 Convertible promissory notes payable, related parties, in default: Total convertible promisory notes payable, related parties, in default In default 14.0 % $ 0.10 1,596 - - 1,596 SBA loan # February 20, 2026 1.00 % n/a 1,033 - - 1,033 Advances on future cash receipts June 13, 2022 n/a n/a 925 (509 ) - 416 Total debt outstanding, including amounts in default 27,999 (7,103 ) 4,575 25,471 Less: current maturities, including notes in default (27,192 ) 7,103 (4,575 ) (24,664 ) Total long-term debt as of March $ 807 $ - $ - $ 807 As of 12 / / (dollars in s) Maturity Date Interest Rate Conversion Price Principal Remaining Debt Discount Remaining Embedded Conversion Option Carrying Value Senior secured promissory note payable, in default In default 20.25 % n/a $ 15,000 (3,414 ) - $ 11,586 Convertible promissory notes payable, in default: Total convertible promisory notes payable, in default In default 15.40 % $ 0.1071 6,445 (1,099 ) 6,255 11,601 Convertible promissory notes payable, related parties, in default: Total convertible promisory notes payable, related parties, in default In default 14.0 % $ 0.10 1,596 - - 1,596 SBA loan # February 20, 2026 1.00 % n/a 1,033 - - 1,033 Advances on future cash receipts March 11, 2022 n/a n/a 1,500 (1,054 ) - 446 Total debt outstanding, including amounts in default 25,574 (5,567 ) 6,255 26,262 Less: current maturities, including notes in default (24,699 ) 5,567 (6,255 ) (25,387 ) Total long-term debt as of December $ 875 $ - $ - $ 875 Senior secured promissory note payable, in default (“Senior Secured Note”) - On February the Company entered into a Note Extension with NH Expansion Credit Fund Holdings LP. The amount of the note was , with an interest rate of and matures on September 30, 2025 Because the combined fair value of the applicable warrants and common stock issued as part of this note exceeded the face value of the note, the additional amount beyond the face value is recorded as a loss on issuance of . Embedded Conversion Option Liability The fair value of Conversion Option liability was determined by using a binomial pricing model: At / / At / / Conversion Price (1) $ 0.11 $ 0.11 Interest Rate (annual) (2) 0.15 % 0.18 % Volatility (annual) (3) 185.75 % 289.65 % Time to Maturity (Years) 0.26 0.50 (1) Based on the terms provided in the warrant agreement to purchase common stock of the Company as of March and December (2) (3)

Common Stock Purchase Warrants

Common Stock Purchase Warrants	3 Months Ended
	Mar. 31, 2022
Common Stock Purchase Warrants [Abstract]
Common Stock Purchase Warrants	9. Common Stock Purchase Warrants A summary of the warrant activity as of March is as follows (dollars in s): Warrants Weighted Average Exercise Price per share Weighted Average Remaining Contractual Life (years) Outstanding at December 204,882,664 $ 0.20 2.54 Exercised (15,909,091 ) 0.01 Issued 16,152,079 0.18 Outstanding at March 205,125,652 $ 0.18 2.67 On January the Company issued 14,000,000 shares of its common stock to LGH upon the cashless exercise of of the LGH Warrants under the terms of the warrant agreement. After this cashless exercise, of LGH Warrants remain outstanding. On February the Company issued 16.1 warrants with an exercise price of and a -year term as part of the Amendment to Note and Warrant Purchase and Security Agreement with NH Expansion Fund.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Measurements [Abstract]
Fair Value Measurements	10. Fair Value Measurements In accordance with ASC 820 (Fair Value Measurements and Disclosures), the Company uses various inputs to measure the outstanding warrants and certain embedded conversion features associated with a convertible debt on a recurring basis to determine the fair value of the liability. The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of March 31, 2022 and 2021 (in thousands): Fair value measured at March 31, 2022 Fair value at March 31, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Warrant liability $ 8,300 $ - $ - $ 8,300 Embedded conversion option 4,575 - - 4,575 Total fair value 12,875 - - 12,875 Fair value measured at December 31, 2021 Fair value at December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Warrant liability $ 9,614 - - 9,614 Embedded conversion option 6,255 - - 6,255 Total fair value 15,869 - - 15,869 There were no transfers between Level 1, 2 or 3 during the three months ended March 31, 2022 and 2021. The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2022. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g. changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs (dollars in thousands): Warrant Liability Conversion Feature Total Balance at December 31, 2021 $ 9,614 $ 6,255 $ 15,869 Cashless exercise (2,167 ) - (2,167 ) Warrants issued 2,654 - 2,654 Change in fair value (1,801 ) (1,680 ) (3,481 ) Balance at March 31 2022 $ 8,300 $ 4,575 $ 12,875 A summary of the warrant liability activity for the three months ended March 31, 2022 is as follows: Warrants Outstanding Fair Value per Share Fair Value Balance at December 31, 2021 62,617,188 $ 0.15 $ 9,614,134 Warrants classified as liabilities (15,000,000 ) 0.14 (2,167,022 ) Warrants issued 16,152,079 0.18 2,654,178 Gain on remeasurement of warrant liability - (1,801,225 ) Balance at March 31 2022 63,769,267 $ 0.13 $ 8,300,065 Significant Black Scholes valuation model inputs related to the Company’s different Warrants are listed below. March 31, 2022 December 31, 2021 New Issuances at Issue Date Weighted average remaining life in years 5.65 4.67 8.63 Weighted average volatility 131 % 116 % 143 % Weighted average risk free interest rate 2.2 % 1.2 % 2.0 % Expected dividend yield 0.00 % 0.00 % 0.00 %

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies In the ordinary course of business, the Company from time to time becomes involved in various legal proceedings involving a variety of matters. The Company does not believe there are any pending legal proceedings that will have a material adverse effect on the Company’s business, consolidated financial position, results of operations, or cash flows. However, the outcome of such legal matters is inherently unpredictable and subject to significant uncertainties. The Companies expenses legal fees in the period in which they are occurred. Supplier disputes

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	12. Related Party Transactions Advance from Director The Stolarski Advance has 18 UltraMIST® systems used as collateral (the “Collateral”) and the Company has agreed to repurchase the Collateral at $256 thousand.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events May 2022 Advance on Future Receipts Financing

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Estimates	Estimates Significant estimates include the recording of allowances for doubtful accounts, the net realizable value of inventory, useful lives of long-lived assets, fair value of goodwill and other intangible assets, the determination of the valuation allowances for deferred taxes, estimated fair value of stock-based compensation, and the estimated fair value of financial instruments, including warrants and embedded conversion options.

Loss per Share (Tables)

Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Loss per Share [Abstract]
Weighted Average Shares Outstanding	Accordingly, warrants issued with a $0.01 per share exercise price, are included in weighted average shares outstanding as follows (shares in s): Three Months Ended March 31, 2022 March 31, 2021 Weighted average shares outstanding Common shares 498,723 481,620 Common shares issuable assuming excercise of nominally priced warrants 26,691 36,871 Weighted average shares outstanding 525,414 518,491
Anti-dilutive Equity Securities	Anti-dilutive equity securities consist of the following at March 31, 2022 and 2021, respectively (in s): 2022 2021 Common stock options 31,759 31,864 Common stock purchase warrants 183,435 142,266 Convertible notes payable 94,172 60,329 309,366 234,459

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Accrued Expenses [Abstract]
Accrued Expenses	Accrued expenses consist of the following at March and December (in s): 2022 2021 Registration penalties $ 2,083 $ 1,950 License fees 893 893 Board of director’s fees 537 507 Related party 250 - Other 1,153 1,044 $ 4,916 $ 4,394

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue [Abstract]
Disaggregation of Revenue	The disaggregation of revenue is based on geographical region. All revenue is recognized at the point in time when control is transferred to our clients. The following tables present revenue from contracts with customers for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, 2022 Three Months Ended March 31, 2021 United States International Total United States International Total Accessories and parts $ 2,132 $ (4 ) $ 2,128 $ 1,435 $ 136 $ 1,571 Product 691 16 707 41 212 253 License fees and other 8 9 17 33 5 38 Topic 606 Revenue $ 2,831 $ 21 $ 2,852 $ 1,509 $ 353 $ 1,862 Rental income 343 - 343 254 - 254 Topic 842 Revenue $ 343 $ - $ 343 $ 254 $ - $ 254 Total Revenue $ 3,174 $ 21 $ 3,195 $ 1,763 $ 353 $ 2,116
Contract Liabilities	The following table summarizes the changes in contract liabilities during the months ended March (in s): Three Months ended March 31, 2022 Three Months ended March 31, 2021 Beginning balance $ 341 $ 69 New service agreement additions 28 1 Deposit on future equipment purchases - 125 Revenue recognized (8 ) (8 ) Total contract liabilities 361 187 Less current portion (58 ) (32 ) Non-current contract liabilities $ 303 $ 155

Concentration of Credit Risk _2

Concentration of Credit Risk and Limited Suppliers (Tables)	3 Months Ended
	Mar. 31, 2022
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration of Credit Risk and Limited Suppliers	Major customers are defined as customers whose accounts receivable, or sales individually consist of more than ten percent of total trade receivables or total sales, respectively. The percentage of accounts receivable and sales from major customers of the Company for the periods indicated were as follows: March 31, 2022 December 31, 2021 Accounts Receivable: Customer A 15 % 16 % Customer B n/a 24 % March 31, 2022 March 31, Revenue: Customer A 11 % n/a The Company currently purchases most of its product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. The of purchases from major vendors of the Company that exceeded of total purchases for the months ended March and were as follows: Three Months Ended March 31, 2022 March 31, 2021 Purchases: Vendor A 19 % 55 % Vendor B n/a 13 %

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Payable [Abstract]
Outstanding Notes Payable	The following tables summarize outstanding notes payable as of March and December (dollars in s): A s of 03 / / (dollars in s) Maturity Date Interest Rate Conversion Price Principal Remaining Debt Discount Remaining Embedded Conversion Option Carrying Value Senior secured promissory note payable, in default In default 20.50 % n/a $ 18,000 (6,106 ) - $ 11,894 Convertible promissory notes payable, in default: Total convertible promisory notes payable, in default In default 15.40 % $ 0.1058 6,445 (488 ) 4,575 10,532 Convertible promissory notes payable, related parties, in default: Total convertible promisory notes payable, related parties, in default In default 14.0 % $ 0.10 1,596 - - 1,596 SBA loan # February 20, 2026 1.00 % n/a 1,033 - - 1,033 Advances on future cash receipts June 13, 2022 n/a n/a 925 (509 ) - 416 Total debt outstanding, including amounts in default 27,999 (7,103 ) 4,575 25,471 Less: current maturities, including notes in default (27,192 ) 7,103 (4,575 ) (24,664 ) Total long-term debt as of March $ 807 $ - $ - $ 807 As of 12 / / (dollars in s) Maturity Date Interest Rate Conversion Price Principal Remaining Debt Discount Remaining Embedded Conversion Option Carrying Value Senior secured promissory note payable, in default In default 20.25 % n/a $ 15,000 (3,414 ) - $ 11,586 Convertible promissory notes payable, in default: Total convertible promisory notes payable, in default In default 15.40 % $ 0.1071 6,445 (1,099 ) 6,255 11,601 Convertible promissory notes payable, related parties, in default: Total convertible promisory notes payable, related parties, in default In default 14.0 % $ 0.10 1,596 - - 1,596 SBA loan # February 20, 2026 1.00 % n/a 1,033 - - 1,033 Advances on future cash receipts March 11, 2022 n/a n/a 1,500 (1,054 ) - 446 Total debt outstanding, including amounts in default 25,574 (5,567 ) 6,255 26,262 Less: current maturities, including notes in default (24,699 ) 5,567 (6,255 ) (25,387 ) Total long-term debt as of December $ 875 $ - $ - $ 875
Fair Value of Conversion Option liability	The fair value of Conversion Option liability was determined by using a binomial pricing model: At / / At / / Conversion Price (1) $ 0.11 $ 0.11 Interest Rate (annual) (2) 0.15 % 0.18 % Volatility (annual) (3) 185.75 % 289.65 % Time to Maturity (Years) 0.26 0.50 (1) Based on the terms provided in the warrant agreement to purchase common stock of the Company as of March and December (2) (3)

Common Stock Purchase Warrants

Common Stock Purchase Warrants (Tables)	3 Months Ended
	Mar. 31, 2022
Common Stock Purchase Warrants [Abstract]
Warrant Activity	A summary of the warrant activity as of March is as follows (dollars in s): Warrants Weighted Average Exercise Price per share Weighted Average Remaining Contractual Life (years) Outstanding at December 204,882,664 $ 0.20 2.54 Exercised (15,909,091 ) 0.01 Issued 16,152,079 0.18 Outstanding at March 205,125,652 $ 0.18 2.67

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Measurements [Abstract]
Liabilities Measured at Fair Value on Recurring Basis	The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of March 31, 2022 and 2021 (in thousands): Fair value measured at March 31, 2022 Fair value at March 31, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Warrant liability $ 8,300 $ - $ - $ 8,300 Embedded conversion option 4,575 - - 4,575 Total fair value 12,875 - - 12,875 Fair value measured at December 31, 2021 Fair value at December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Warrant liability $ 9,614 - - 9,614 Embedded conversion option 6,255 - - 6,255 Total fair value 15,869 - - 15,869
Warrants Outstanding and Fair Values	The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2022. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g. changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs (dollars in thousands): Warrant Liability Conversion Feature Total Balance at December 31, 2021 $ 9,614 $ 6,255 $ 15,869 Cashless exercise (2,167 ) - (2,167 ) Warrants issued 2,654 - 2,654 Change in fair value (1,801 ) (1,680 ) (3,481 ) Balance at March 31 2022 $ 8,300 $ 4,575 $ 12,875 A summary of the warrant liability activity for the three months ended March 31, 2022 is as follows: Warrants Outstanding Fair Value per Share Fair Value Balance at December 31, 2021 62,617,188 $ 0.15 $ 9,614,134 Warrants classified as liabilities (15,000,000 ) 0.14 (2,167,022 ) Warrants issued 16,152,079 0.18 2,654,178 Gain on remeasurement of warrant liability - (1,801,225 ) Balance at March 31 2022 63,769,267 $ 0.13 $ 8,300,065
Fair Value of Warrant Liabilities Using Black-Scholes Model	Significant Black Scholes valuation model inputs related to the Company’s different Warrants are listed below. March 31, 2022 December 31, 2021 New Issuances at Issue Date Weighted average remaining life in years 5.65 4.67 8.63 Weighted average volatility 131 % 116 % 143 % Weighted average risk free interest rate 2.2 % 1.2 % 2.0 % Expected dividend yield 0.00 % 0.00 % 0.00 %

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation (Details)	Aug. 06, 2020Product
Nature of the Business and Basis of Presentation [Abstract]
Number of energy transfer technology products	2
Number of human tissues biological products	2

Loss per Share, Weighted Averag

Loss per Share, Weighted Average Shares Outstanding (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Weighted Average Shares Outstanding [Abstract]
Weighted average shares outstanding (in shares)	525,414	518,491
Warrant exercise price (in dollars per share)	$ 0.01
Common Shares [Member]
Weighted Average Shares Outstanding [Abstract]
Weighted average shares outstanding (in shares)	498,723	481,620
Common Shares Issuable Assuming Exercise of Nominally Priced Warrants [Member]
Weighted Average Shares Outstanding [Abstract]
Weighted average shares outstanding (in shares)	26,691	36,871

Loss per Share, Anti Dilutive E

Loss per Share, Anti Dilutive Equity Securities (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	309,366	234,459
Common Stock Options [Member]
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	31,759	31,864
Common Stock Purchase Warrants [Member]
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	183,435	142,266
Convertible Notes Payable [Member]
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	94,172	60,329

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Accrued Expense [Abstract]
Registration penalties	$ 2,083	$ 1,950
License fees	893	893
Board of director's fees	537	507
Related party	250	0
Other	1,153	1,044
Total accrued expenses	4,916	$ 4,394
Warranty reserve accrual	$ 0

Revenue, Disaggregation of Reve

Revenue, Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Abstract]
Revenue	$ 2,852	$ 1,862
Rental income	343	254
Total Revenues	3,195	2,116
Accessories and Parts [Member]
Disaggregation of Revenue [Abstract]
Revenue	2,128	1,571
Product [Member]
Disaggregation of Revenue [Abstract]
Revenue	707	253
Total Revenues	645	253
License Fees and Other [Member]
Disaggregation of Revenue [Abstract]
Revenue	17	38
United States [Member]
Disaggregation of Revenue [Abstract]
Revenue	2,831	1,509
Rental income	343	254
Total Revenues	3,174	1,763
United States [Member] | Accessories and Parts [Member]
Disaggregation of Revenue [Abstract]
Revenue	2,132	1,435
United States [Member] | Product [Member]
Disaggregation of Revenue [Abstract]
Revenue	691	41
United States [Member] | License Fees and Other [Member]
Disaggregation of Revenue [Abstract]
Revenue	8	33
International [Member]
Disaggregation of Revenue [Abstract]
Revenue	21	353
Rental income	0	0
Total Revenues	21	353
International [Member] | Accessories and Parts [Member]
Disaggregation of Revenue [Abstract]
Revenue	(4)	136
International [Member] | Product [Member]
Disaggregation of Revenue [Abstract]
Revenue	16	212
International [Member] | License Fees and Other [Member]
Disaggregation of Revenue [Abstract]
Revenue	$ 9	$ 5

Revenue, Contract Liabilities (

Revenue, Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Contract liabilities [Abstract]
Total contract liabilities	$ 361	$ 187	$ 341	$ 69
Less: current portion	(58)	(32)	(48)
Non-current contract liabilities	303	155	293
Revenue related to contract liabilities	(8)	(8)
Service Agreements [Member]
Contract liabilities [Abstract]
Total contract liabilities	361		137
Deposit on Future Equipment Purchases [Member]
Contract liabilities [Abstract]
Total contract liabilities	0	125	$ 204
New Service Agreement Additions [Member]
Contract liabilities [Abstract]
Total contract liabilities	$ 28	$ 1

Concentration of Credit Risk _3

Concentration of Credit Risk and Limited Suppliers (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer A [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage	15.00%		16.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer B [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage			24.00%
Revenue [Member] | Customer Concentration Risk [Member] | Customer B [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage	11.00%
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor A [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage	19.00%	55.00%
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor B [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage		13.00%

Notes Payable, Outstanding Note

Notes Payable, Outstanding Notes Payable (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Senior Secured Promissory Notes Payable [Abstract]
Long-term debt gross	$ 27,999	$ 25,574
Long-term debt gross, current	(27,192)	(24,699)
Long-term debt gross, noncurrent	807	875
Remaining debt discount	(7,103)	(5,567)
Senior secured promissory note payable, in default	11,894	11,586
Remaining debt discount, current	7,103	5,567
Remaining debt discount, noncurrent	0	0
Remaining embedded conversion option	4,575	6,255
Remaining embedded conversion option, current	(4,575)	(6,255)
Remaining embedded conversion option, noncurrent	0	0
Convertible promissory note payable, in default	10,532	11,601
Advances on future cash receipts	416	446
Debt, Long-term and Short-term, Combined Amount [Abstract]
Long-term debt net	25,471	26,262
Long-term debt net, current	(24,664)	(25,387)
Long-term debt net, noncurrent	$ 807	$ 875
Convertible Notes Payable [Member]
Senior Secured Promissory Notes Payable [Abstract]
Maturity date	In default
Interest rate	14.00%	14.00%
Conversion price (in dollars per share)	$ 0.10	$ 0.10
Principal amount	$ 1,596	$ 1,596
Remaining debt discount	0	0
Remaining embedded conversion option	0	0
Convertible promissory notes payable, related parties, in default	$ 1,596	$ 1,596
SBA Loan #2 [Member]
Senior Secured Promissory Notes Payable [Abstract]
Maturity date	Feb. 20, 2026
Interest rate	1.00%	1.00%
Principal amount	$ 1,033	$ 1,033
Remaining debt discount	0	0
Remaining embedded conversion option	0	0
SBA loans	$ 1,033	$ 1,033
Advances on Future Cash Receipts [Member]
Senior Secured Promissory Notes Payable [Abstract]
Maturity date	Jun. 13, 2022	Mar. 11, 2022
Principal amount	$ 925	$ 1,500
Remaining debt discount	(509)	(1,054)
Remaining embedded conversion option	0	0
Advances on future cash receipts	$ 416	$ 446
Senior Secured Note [Member]
Senior Secured Promissory Notes Payable [Abstract]
Maturity date	In default
Interest rate	20.50%	20.25%
Principal amount	$ 18,000	$ 15,000
Remaining debt discount	(6,106)	(3,414)
Senior secured promissory note payable, in default	11,894	11,586
Remaining embedded conversion option	$ 0	$ 0
Convertible Debt [Member]
Senior Secured Promissory Notes Payable [Abstract]
Maturity date	In default
Interest rate	15.40%	15.40%
Conversion price (in dollars per share)	$ 0.1058	$ 0.1071
Principal amount	$ 6,445	$ 6,445
Remaining debt discount	(488)	(1,099)
Remaining embedded conversion option	4,575	6,255
Convertible promissory note payable, in default	$ 10,532	$ 11,601

Notes Payable, Senior Secured P

Notes Payable, Senior Secured Promissory Note Payable, in Default (Details) - Senior Secured Note [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Feb. 25, 2022	Dec. 31, 2021
Senior Secured Promissory Notes Payable [Abstract]
Principal amount	$ 18,000		$ 15,000
Interest rate	20.50%		20.25%
NH Expansion Credit Fund Holdings LP [Member]
Senior Secured Promissory Notes Payable [Abstract]
Principal amount		$ 3,000
Interest rate		20.50%
Maturity date	Sep. 30, 2025
Loss on issuance		$ 3,400

Notes Payable, Embedded Convers

Notes Payable, Embedded Conversion Option Liability (Details) - Binomial Pricing Model [Member]		3 Months Ended	12 Months Ended
		Mar. 31, 2022$ / shares	Dec. 31, 2021$ / shares
Measurement Input, Conversion Price [Member]
Embedded Conversion Option Liability [Abstract]
Conversion Price (in dollars per share)	[1]	$ 0.11	$ 0.11
Measurement Input, Interest Rate (annual) [Member]
Embedded Conversion Option Liability [Abstract]
Measurement input	[2]	0.0015	0.0018
Measurement Input, Volatility (annual) [Member]
Embedded Conversion Option Liability [Abstract]
Measurement input	[3]	1.8575	2.8965
Measurement Input, Time to Maturity (Years) [Member]
Embedded Conversion Option Liability [Abstract]
Time to Maturity (Years)		3 months 3 days	6 months
[1]	Based on the terms provided in the warrant agreement to purchase common stock of the Company as of March 31, 2022 and December 31, 2021.
[2]	Interest rate for U.S. Treasury Bonds, as of each presented period ending date, as published by the U.S. Federal Reserve.
[3]	Based on the historical daily volatility of the Company as of each presented period ending date.

Common Stock Purchase Warrant_2

Common Stock Purchase Warrants (Details) - $ / shares	Feb. 28, 2022	Jan. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Warrants [Abstract]
Outstanding, beginning (in shares)			204,882,664
Exercised (in shares)			(15,909,091)
Issued (in shares)			16,152,079
Outstanding, ending (in shares)			205,125,652	204,882,664
Weighted Average Exercise Price per share [Abstract]
Outstanding, beginning (in dollars per share)			$ 0.20
Exercised (in dollars per share)			0.01
Issued (in dollars per share)			0.18
Outstanding, ending (in dollars per share)			$ 0.18	$ 0.20
Weighted Average Remaining Contractual Life (Years) [Abstract]
Weighted Average Remaining Contractual Life (years)			2 years 8 months 1 day	2 years 6 months 14 days
Issued (in shares)			16,152,079
NH Expansion Fund [Member]
Weighted Average Exercise Price per share [Abstract]
Outstanding, ending (in dollars per share)	$ 0.18
Weighted Average Remaining Contractual Life (Years) [Abstract]
Issued (in shares)	16,100,000
Warrants term Period			8 years 7 months 6 days
LGH Warrants [Member]
Warrants [Abstract]
Exercised (in shares)		(15,000,000)
Outstanding, ending (in shares)		8,600,000
Weighted Average Remaining Contractual Life (Years) [Abstract]
Issued (in shares)		14,000,000

Fair Value Measurements, Liabil

Fair Value Measurements, Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]
Transfer from level 1 to level 2	$ 0	$ 0
Transfer to level 1 from level 2	0	0
Transfer to level 3	0	0
Transfer from level 3	0	$ 0
Recurring [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	12,875		$ 15,869
Recurring [Member] | Warrant Liability [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	8,300		9,614
Recurring [Member] | Embedded Conversion Option [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	4,575		6,255
Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	0		0
Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | Warrant Liability [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	0		0
Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | Embedded Conversion Option [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	0		0
Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	0		0
Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member] | Warrant Liability [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	0		0
Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member] | Embedded Conversion Option [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	0		0
Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	12,875		15,869
Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member] | Warrant Liability [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	8,300		9,614
Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member] | Embedded Conversion Option [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	$ 4,575		$ 6,255

Fair Value Measurements, Warran

Fair Value Measurements, Warrants Fair Value, Outstanding and Valuation Model (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares	Feb. 28, 2022	Dec. 31, 2021USD ($)$ / sharesshares
Fair Value, Warrant Liability [Abstract]
Warrant Liability, Fair Value	$ 8,300,065		$ 9,614,134
Warrants issued	2,654,178
Gain on remeasurement of warrant liability	$ (1,801,225)
Warrant Outstanding and Fair Value [Abstract]
Warrants outstanding (in shares) | shares	63,769,267		62,617,188
Warrants issued (in shares) | shares	16,152,079
Warrants issued (in dollars per share) | $ / shares	$ 0.18
Gain on remeasurement of warrant liability (in shares) | shares	0
Fair value per share (in dollars per share) | $ / shares	$ 0.13		$ 0.15
Measurement Input, Weighted Average Expected Life in Years [Member]
Black Scholes Option Pricing Model [Abstract]
Weighted average expected life in years (Years)	5 years 7 months 24 days	8 years 7 months 17 days	4 years 8 months 1 day
Measurement Input, Weighted Average Volatility (annual) [Member]
Black Scholes Option Pricing Model [Abstract]
Warrants measurement input	1.31	1.43	1.16
Measurement Input, Weighted Average Risk Free Interest Rate [Member]
Black Scholes Option Pricing Model [Abstract]
Warrants measurement input	0.022	0.020	0.012
Measurement Input, Expected Dividend Yield [Member]
Black Scholes Option Pricing Model [Abstract]
Warrants measurement input	0	0	0
Warrant Classified [Member]
Fair Value, Warrant Liability [Abstract]
Warrant Liability, Fair Value	$ (2,167,022)
Warrant Outstanding and Fair Value [Abstract]
Warrants outstanding (in shares) | shares	(15,000,000)
Fair value per share (in dollars per share) | $ / shares	$ 0.14
Level 3 [Member]
Fair Value, Warrant Liability [Abstract]
Warrant Liability, Fair Value	$ 12,875		$ 15,869
Warrants issued	2,654
Cashless exercise	(2,167)
Gain on remeasurement of warrant liability	(3,481)
Level 3 [Member] | Warrant Liability [Member]
Fair Value, Warrant Liability [Abstract]
Warrant Liability, Fair Value	8,300		9,614
Warrants issued	2,654
Cashless exercise	(2,167)
Gain on remeasurement of warrant liability	(1,801)
Level 3 [Member] | Conversion Feature [Member]
Fair Value, Warrant Liability [Abstract]
Warrant Liability, Fair Value	4,575		$ 6,255
Warrants issued	0
Cashless exercise	0
Gain on remeasurement of warrant liability	$ (1,680)

Related Party Transactions (Det

Related Party Transactions (Details) - A. Michael Stolarski [Member] - April 2022 Advances from Directors [Member] $ in Thousands	Mar. 31, 2022USD ($)Systems
Related Party Transaction Disclosures [Abstract]
Advances from related parties	$ 250
UltraMIST Devices [Member]
Related Party Transaction Disclosures [Abstract]
Number of systems used as collateral | Systems	18
Repurchase of collateral amount	$ 256

Subsequent Events, May 2022 Adv

Subsequent Events, May 2022 Advances on Future Receipts Financing (Details) $ / shares in Units, $ in Thousands	May 19, 2022USD ($)wk$ / sharesshares	Mar. 31, 2022$ / shares	Dec. 31, 2021$ / shares
Subsequent Event [Abstract]
Warrant exercise price (in dollars per share) | $ / shares		$ 0.18	$ 0.20
Subsequent Event [Member] | May 2022 Advances on Future Receipts Financing [Member]
Subsequent Event [Abstract]
Balance paid	$ 400
Cash proceeds	545
Sale of future receipts	$ 1,000
Non-recourse agreement term | wk	24
Minimum amount of receipts, payment	$ 59
Receipts of remaining term | wk	24
Warrants to purchase common stock (in shares) | shares	5,555,556
Warrant exercise price (in dollars per share) | $ / shares	$ 0.18
Warrants expire term	4 years